Teachers Advisors LLC grew its stake in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) by 360.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 22,718 shares of the company’s stock after acquiring an additional 17,785 shares during the quarter. Teachers Advisors LLC owned about 0.09% of Syros Pharmaceuticals worth $366,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Bank of New York Mellon Corp increased its stake in shares of Syros Pharmaceuticals by 157.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 30,024 shares of the company’s stock valued at $483,000 after acquiring an additional 18,382 shares during the last quarter. Wells Fargo & Company MN acquired a new position in shares of Syros Pharmaceuticals during the 1st quarter valued at about $225,000. Schwab Charles Investment Management Inc. acquired a new position in shares of Syros Pharmaceuticals during the 2nd quarter valued at about $343,000. Finally, Rhumbline Advisers acquired a new position in shares of Syros Pharmaceuticals during the 2nd quarter valued at about $198,000. 54.15% of the stock is owned by institutional investors.
Shares of Syros Pharmaceuticals, Inc. (SYRS) opened at $11.62 on Thursday. Syros Pharmaceuticals, Inc. has a 1 year low of $10.22 and a 1 year high of $24.38.
Syros Pharmaceuticals (NASDAQ:SYRS) last posted its earnings results on Wednesday, November 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.53). sell-side analysts anticipate that Syros Pharmaceuticals, Inc. will post -2.09 earnings per share for the current year.
A number of research firms have recently commented on SYRS. JMP Securities downgraded shares of Syros Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 10th. Wedbush reaffirmed an “outperform” rating and set a $22.84 price objective (down previously from $25.00) on shares of Syros Pharmaceuticals in a research note on Thursday, August 10th. Cowen and Company reaffirmed a “buy” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, August 9th. Cann reaffirmed a “buy” rating and set a $28.00 price objective on shares of Syros Pharmaceuticals in a research note on Monday, August 21st. Finally, Zacks Investment Research downgraded shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $26.14.
Syros Pharmaceuticals Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Want to see what other hedge funds are holding SYRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syros Pharmaceuticals, Inc. (NASDAQ:SYRS).
Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.